All In MedTech

FDA Clearance Tracker · P190031

HER2 Dual ISH DNA Probe Cocktail

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jul 28, 2020 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jul 28, 2020

Approved (reclassified)

Time to decision

242 days

Received Nov 29, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class II

The decision

FDA number
P190031
Device name
HER2 Dual ISH DNA Probe Cocktail
Applicant location
Tucson, AZ
Received
Nov 29, 2019
Decided
Jul 28, 2020
Decision
Approved (reclassified)
Supplements
14 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 864.1890

Every decision under product code NYQ

FDA's approval statement

As written in FDA's record.

Approval for the VENTANA HER2 Dual ISH DNA Probe Cocktail assay.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NYQ. The earliest in FDA's data is P050040, decided Jul 1, 2008.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Ventana Medical Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.